Non-Small Cell Lung Cancer
Conditions
Brief summary
1. Recently a radomized trial of vinorelbine versus best supportive care in patients at 70 years of age or older demonstrated a definite improvement in overall survival rate and quality of life with chemotherapy. 2. The role of combination therapy containing the platinum compound, which is the standard therapy for the young patients is still vague. 3. Gemcitabine and carboplatin have favorable toxicity profile.
Interventions
DRUGvinorelbine, gemcitabine and carboplatin
Sponsors
Inje University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with pathologically confirmed, advanced(clinical stage IIIB or IV) NSCLC * No previous chemotherapy history * Age ≥ 65 years * ECOG performance status ≤ 2 * Adequate marrow function (ANC ≥ 2,000/mm3, platelet ≥ 100,000/mm3), renal and liver function (total bilirubin \< 2.0 mg/dL, AST/ALT levels \< 3 × the upper limit of normal, serum creatinine \< 2.0 mg/dL) * Patients with informed written consent
Exclusion criteria
* Patients with other major illness(active infection, severe heart disease, concomitant malignancy, etc)
Countries
South Korea
Contacts
Primary ContactYoung Jin Yuh, M.D.
Outcome results
None listed